Elixxer

Elixxer Financial Leverage

The Financial Leverage (Equity Multiplier) of Elixxer (ELXR.H.V) as of Oct 16, 2026 is -0.29. In the previous year, Financial Leverage (Equity Multiplier) was -0.96 — a change of -69.57% (higher).

Financial Leverage

-0.29

YoY

-69.57%

Last updated:

Financial Leverage (Equity Multiplier) of Elixxer is 2023 -0.29 . Financial Leverage (Equity Multiplier) of Elixxer was 2022 -0.96 . It decreases by -69.57% higher compared to the previous year.

The Elixxer Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2016
1.07 CAD
Jan 1, 2017
1.74 CAD
Jan 1, 2018
1.17 CAD
Jan 1, 2019
1.82 CAD
Jan 1, 2020
4.37 CAD
Jan 1, 2021
2.01 CAD
Jan 1, 2022
-0.96 CAD
Jan 1, 2023
-0.29 CAD
The Elixxer Financial Leverage history
YEARFinancial LeverageYoY
-0.29-69.57%
-0.96-147.84%
2.01-54.07%
4.37+140.62%
1.82+54.93%
1.17-32.68%
1.74+63.40%
1.07-95.57%
24.10+1,900.31%
1.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd, trading under the ticker ELXR.H.V and registered with ISIN CA28660W20004, is a company based in Montreal, Canada. It operates within the Financial Services sector, specifically in the Financials industry. The company completed its initial public offering on November 24, 2005. Elixxer Ltd maintains a website at https://www.elixxer.com/. The company's primary focus involves investments in cannabis-related businesses, including entities licensed for the cultivation, production, and sale of cannabis and cannabis-derived products. Its investment portfolio spans various segments of the cannabis industry, such as nutraceuticals, cosmetics, pharmaceuticals, cultivation, and extraction. The firm emphasizes medical cannabis and specialty cannabis-derived products within the pharmaceutical sector. Elixxer Ltd also engages in the cultivation and production of medical-grade cannabis for global markets. Additionally, the company develops and produces Cannabidiol (CBD) cosmetics and natural wellness products. It invests in facilities dedicated to the cultivation, extraction, and production of legal cannabis products. The company's brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis. Elixxer Ltd holds investments in cannabis companies across multiple countries, including Australia, Canada, Switzerland, Italy, and Jamaica. Subsidiaries of the company include LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. Elixxer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elixxer stock

Financial Leverage (Equity Multiplier) of Elixxer is -0.29 in 2023.

Financial Leverage (Equity Multiplier) of Elixxer changed from -0.96 to -0.29, representing a -69.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Elixxer since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Elixxer with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Elixxer

All Key Metrics — Elixxer